NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
Key Highlights
- ➤NRx Pharmaceuticals (NRXP) begins U.S. sales of preservative-free ketamine.
- ➤17-person sales force reaches customers controlling approximately 80% of U.S. ketamine sales.
- ➤Initial supply agreements and preorders target late 2026; shipments begin January 2027.
- ➤NRx expects gross and net sales margins exceeding 50%.
- ➤NRx contracted German suppliers to double South Carolina BFS manufacturing capacity.
Expert Statements
Jonathan Javitt, Chief Executive Officer of NRx Pharmaceuticals
“By enlisting seasoned sales representatives who already sell sterile injectable drugs, we are able to drive considerable efficiency in costs of sales and marketing,”
Jonathan Javitt, Chief Executive Officer of NRx Pharmaceuticals
“Our representatives already have strong relationships with hospital and group purchasing responsible for the vast majority of ketamine and other sterile injectable drugs sold in the U.S.”
* A veteran, trained, and certified 17-person sales force, commenced sales operations this week, providing national coverage with customers responsible for approximately 80% of current U.S. ketamine sales * Initial supply agreements and preorders are targeted for late 2026, with product shipments scheduled to begin in January 2027 * Efficiencies in blow-fill-seal (BFS) manufacturing and the sales structure are expected to result in gross and net sales margins in excess of 50%, margins commonly associated with innovative drugs * Innovative, drug/device combination vial provides barriers to competition * NRx has contracted with German suppliers for additional BFS manufacturing lines to expand its sterile injectable portfolio through the new sales channels WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, today announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2018.
Get started
Create a free account to read the full story.